RPD

Rapid7, Inc.
$12.20
+0.03 (+0.25%)
Mkt Cap 815.33M
Volume 1,911,997
52W Range 4.97-23.26
Sector Technology
Beta 1.01
EPS (TTM) 0.34
P/E Ratio 35.38
Revenue (TTM) 859.23M
Rev Growth (5Y) +15.9%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$5.69
Overvalued strong signal
114.3% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 859.79M 844.01M 777.71M 685.08M 535.40M 411.49M 326.95M 244.09M 200.94M 157.44M 110.53M 76.88M
Net Income 23.38M 25.53M (149.26M) (124.72M) (146.33M) (98.85M) (53.84M) (55.55M) (45.47M) (49.00M) (49.86M) (32.63M)
EPS 0.36 0.41 -2.46 -2.13 -2.65 -1.94 -1.10 -1.20 -1.06 -1.19 -2.02 -1.05
Free Cash Flow 144.53M 168.25M 99.91M 57.82M 44.91M (8.91M) (30.85M) (6.75M) 8.46M 4.61M (6.04M) (10.44M)
FCF / Share 2.23 2.69 1.64 0.99 0.81 -0.17 -0.63 -0.15 0.20 0.11 -0.24 -0.34
Operating CF 152.13M 171.67M 104.28M 78.20M 53.92M 4.89M (1.42M) 6.07M 13.29M 9.11M (1.91M) (3.36M)
Total Assets 1.73B 1.65B 1.51B 1.36B 1.30B 913.12M 664.91M 559.37M 284.14M 243.30M 230.56M 86.97M
Total Debt 1.03B 1.02B 1.02B 914.34M 912.56M 463.94M 264.67M 174.69M 0 0 0 16.87M
Cash & Equiv 246.66M 334.69M 213.63M 207.29M 164.58M 173.62M 123.41M 99.56M 51.56M 53.15M 86.55M 36.82M
Book Value 154.73M 17.71M (118.18M) (120.07M) (126.00M) 71.54M 83.17M 87.32M 24.15M 42.04M 68.08M (35.26M)
Return on Equity 0.15 1.44 N/A N/A N/A -1.38 -0.65 -0.64 -1.88 -1.17 -0.73 N/A
RPD News
Rapid7 to Report Second Quarter 2026 Financial Results on August 10
Jul 14, 2026 12:05 PM · globenewswire.com
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Jul 13, 2026 05:00 AM · gurufocus.com
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Jul 13, 2026 04:32 AM · businesswire.com
Rapid7 (RPD) Moves 7.6% Higher: Will This Strength Last?
Jun 29, 2026 04:41 AM · zacks.com
Reveal Expands European Offerings with Private Deployment, AI-Powered Review and Logikcull's Government Transparency Solutions
Jun 16, 2026 05:00 AM · businesswire.com
Rapid7 Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Jun 15, 2026 12:05 PM · globenewswire.com
Rapid7: New CEO And AI Opportunities Draw Attention
Jun 09, 2026 12:40 AM · seekingalpha.com
Rapid7 Appoints Wael Mohamed Chief Executive Officer; Corey Thomas to Become Executive Chairman
Jun 01, 2026 03:55 AM · globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rapid7, Inc. - RPD
May 21, 2026 11:45 AM · prnewswire.com
Rapid7 Q1 2026 Threat Landscape Report Finds Vulnerability Exploitation Overtakes Social Engineering as the Top Initial Access Vector
May 21, 2026 05:00 AM · globenewswire.com